Chengdu Kelingyuan Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  SMP-100 / Chengdu Kelingyuan Pharma, ConSynance
    Trial completion, Trial completion date, Trial primary completion date:  A Phase 1 Study of SMP-100 in Normal Healthy Volunteers (clinicaltrials.gov) -  Mar 11, 2022   
    P1,  N=53, Completed, 
    . Active, not recruiting --> Completed | Trial completion date: Apr 2022 --> Aug 2021 | Trial primary completion date: Feb 2022 --> Jul 2021
  • ||||||||||  SMP-100 / Chengdu Kelingyuan Pharma, ConSynance
    Trial completion, Enrollment change, Trial completion date:  3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability (clinicaltrials.gov) -  Mar 11, 2022   
    P1,  N=8, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2022 --> Aug 2021 | Trial primary completion date: Feb 2022 --> Jul 2021 Recruiting --> Completed | N=12 --> 8 | Trial completion date: Mar 2022 --> Dec 2021
  • ||||||||||  SMP-100 / Chengdu Kelingyuan Pharma, ConSynance
    Trial completion date, Trial primary completion date:  A Phase 1 Study of SMP-100 in Normal Healthy Volunteers (clinicaltrials.gov) -  Nov 30, 2021   
    P1,  N=72, Active, not recruiting, 
    Recruiting --> Completed | N=12 --> 8 | Trial completion date: Mar 2022 --> Dec 2021 Trial completion date: Oct 2021 --> Apr 2022 | Trial primary completion date: Aug 2021 --> Feb 2022
  • ||||||||||  SMP-100 / Chengdu Kelingyuan Pharma, ConSynance
    Enrollment closed, Trial completion date, Trial primary completion date:  A Phase 1 Study of SMP-100 in Normal Healthy Volunteers (clinicaltrials.gov) -  Aug 2, 2021   
    P1,  N=72, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Aug 2021
  • ||||||||||  SMP-100 / ConSynance, Xiling Lab
    Clinical, Journal:  CSTI-300; a novel 5-HT receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndrome. (Pubmed Central) -  Sep 9, 2020   
    SIGNIFICANCE STATEMENT: There is a lack of effective current treatment for IBS-d and carcinoid syndrome, and in both conditions, over-activity of the 5-HT receptor is thought to be implicated in the pathophysiology. As 5-HT receptor blockade with antagonists results in significant side effects, we present evidence that treatment with a suitable 5-HT receptor partial agonist will alleviate some symptoms associated with these conditions yet without fully inhibiting the receptor predict a less pronounced side effect profile associated with this therapeutic strategy.
  • ||||||||||  SMP-100 / Chengdu Kelingyuan Pharma, ConSynance
    Enrollment open, Trial completion date, Trial primary completion date:  A Phase 1 Study of SMP-100 in Normal Healthy Volunteers (clinicaltrials.gov) -  Jul 22, 2020   
    P1,  N=72, Recruiting, 
    As 5-HT receptor blockade with antagonists results in significant side effects, we present evidence that treatment with a suitable 5-HT receptor partial agonist will alleviate some symptoms associated with these conditions yet without fully inhibiting the receptor predict a less pronounced side effect profile associated with this therapeutic strategy. Not yet recruiting --> Recruiting | Trial completion date: Mar 2021 --> Jul 2021 | Trial primary completion date: Nov 2020 --> Apr 2021